Home Autoimmune conditions: Living With syndicated patient reports

Autoimmune conditions: Living With syndicated patient reports

4 April 2024

The prevalence of autoimmune conditions is increasing, and despite significant advancements in treatments, individuals affected by these diseases may not be receiving the most effective management and care.

In our Living With syndicated patient reports, we have interviewed hundreds of autoimmune patients and caregivers throughout the years. Quantitative and qualitative methodologies are combined to provide powerful insights about patient journeys to diagnosis, and the burden on patients living with conditions such as: Crohn’s Disease, Lupus, Psoriasis, Psoriatic Arthritis, Rheumatoid Arthritis, Systemic Sclerosis and Ulcerative Colitis.

“On bad days my whole body is in agony. Mental anguish, irritability, emotional instability, extremely tired, depressed, and closed off to society”- Female, 43 years old, Lupus Nephritis patient.

While uncovering the patient burden is at the forefront of the Living With reports, we also examine patient perspectives on diagnosis, treatments, physician interactions and support needed.

Whether you need immunology-focused patient journey insights to enhance your pre-launch plans, improve your current communications strategies, or inform your clinical trial planning, the Living With reports are an instrumental addition to your toolkit. Our series of reports also expands a range of other areas, including: Dermatology, Neurology, Oncology and Respiratory.

Click here to learn more about the Living With reports.


We host a Living With Chronic Illness podcast which is designed to give a voice to patients suffering from chronic conditions and ask if our findings mirror their experiences. Over this series we have talked to a number of patients from different countries suffering from a range of conditions. Listen to the podcast here.


Sign up to receive Rapport.

Rapport is our monthly newsletter where we share our latest expertise and experience.